Palisaded Neutrophilic and Granulomatous Dermatitis in Crohn’s Disease under Infliximab Therapy with Concomitant Herpes Zoster Infection: A Case Report
Case Reports in Dermatology · 2026-07-28 · 18 (1) · 646-653
DOI: 10.1159/cde/abvag001 ↗Abstract
Introduction: Palisaded neutrophilic and granulomatous dermatitis (PNGD) is a rare reactive dermatosis characterized clinically by symmetrical erythematous or violaceous umbilicated papules, typically involving acral sites, and histologically by a combination of neutrophilic dermatitis, interstitial granulomatous inflammation, and necrobiotic collagen. PNGD commonly arises in association with systemic conditions, especially autoimmune diseases, inflammatory arthritis, hematologic disorders, inflammatory bowel disease (IBD), infections, or medication exposure. Case Presentation: We report a 52-year-old man with longstanding Crohn’s disease treated with infliximab who developed asymptomatic erythematous papules on the nose, ear helices, and fingers following a recent herpes zoster episode and temporary interruption of infliximab therapy. Histopathology revealed an interstitial band-like infiltrate rich in neutrophils and histiocytes with basophilic necrotic collagen and leukocytoclasia, consistent with PNGD. Topical corticosteroid therapy led to complete resolution within 1 month, and no recurrence occurred after resuming infliximab over 1 year of follow-up. Conclusion: This case highlights the multifactorial nature of PNGD, in which Crohn’s disease, anti-TNF therapy, and post-zoster immune dysregulation may act as synergistic triggers. Although anti-TNF agents are known to both treat and paradoxically induce PNGD, reports in IBD remain uncommon. PNGD shares overlapping histoclinical features with interstitial granulomatous dermatitis and neutrophilic dermatoses, supporting the concept of a spectrum of reactive granulomatous dermatitis. Recognition of PNGD is essential, as it may serve as a marker of underlying systemic disease or immune dysregulation. Management focuses on treating associated conditions, with topical or systemic anti-inflammatory therapies used as adjuncts. Further studies on immunopathogenesis may refine the classification of these overlapping entities.
EUVIMED